This study … emphasizes the concept that adding a biologic agent to a chemotherapy backbone in the correct setting can translate into significantly improved outcomes.
—Nathan Fowler, MD
The ASCO Post asked for comment about the presentation by Nowakowski et al from Nathan Fowler, MD, who developed and led many of the early studies of R-Squared (lenalidomide [Revlimid], rituximab [Rituxan]), in lymphoma as well. Dr. Fowler is Associate Professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, Houston.
“We are very excited about the recent results of R2-CHOP in large cell lymphoma. Historically, the addition of cytotoxic agents to the CHOP combination has failed to show a consistent benefit over CHOP alone,” he said.
“Nowakowski and colleagues have shown that R2-CHOP has significant activity in newly diagnosed patients and have suggested that R2-CHOP can ameliorate the inferior prognosis associated with non–germinal center subtype of [diffuse large B-cell lymphoma]. This study further confirms mounting preclinical evidence that lenalidomide has preferential antitumor activity in non–germinal center [diffuse large B-cell lymphoma] cells and emphasizes the concept that adding a biologic agent to a chemotherapy backbone in the correct setting can translate into significantly improved outcomes.” ■
Disclosure: Dr Fowler has received research funding from and is on the scientific advisory boards of Celgene and Roche.
The combination of lenalidomide (Revlimid) and rituximab (Rituximab), dubbed the “R-squared” regimen, has gained attention lately, and ongoing trials are evaluating whether chemotherapy with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone) can be improved by adding a...